John Aballi is recorded as CFO at Exagen Inc. (XGN) since July 31, 2024 and CEO and Board Member at Exagen Inc. (XGN). The newest filing on record that lists John Aballi as CEO and Board Member at Exagen Inc. (XGN) is dated April 27, 2026. Exagen Inc. reported in an 8-K filed August 2, 2024 that John Aballi was appointed Interim Chief Financial Officer, effective July 31, 2024. Exagen Inc. reported in an 8-K filed October 20, 2022 that John Aballi was appointed member of the Board. Exagen Inc. reported in an 8-K filed October 20, 2022 that John Aballi was appointed member of the board of directors, effective October 16, 2022. Equibles holds 4 filed executive changes naming John Aballi; each is listed under recent activity with its source filing. The proxy statement of Exagen Inc. reports total compensation of $1,400,868 for John Aballi in fiscal 2025, including a base salary of $540,000. Disclosed compensation is on record for 5 fiscal years. John Aballi has spoken on 15 earnings calls and 1 other investor event across 1 company, most recently for Exagen Inc. on August 11, 2026. Exagen Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Exagen Inc. includes Tina S. Nova (Chairman), Jeffrey Black (CFO), Mark Hazeltine (COO) and 6 others.
“On July 31, 2024, the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of July 31, 2024.”
Exagen Inc. Form 8-K, filed August 2, 2024
· Read the filing
“The Exagen Board has appointed Mr. Aballi as CEO, President, and a member of the Board.”
Exagen Inc. Form 8-K, filed October 20, 2022
· Read the filing
John Aballi on recent calls
“So Exogen is a specialty diagnostic lab based in San Diego, California. We focus in the autoimmune, specifically the rheumatology space. We offer proprietary, unique, and comprehensive testing for patients with lupus, rheumatoid arthritis, scleroderma, other types of connective tissue disorders.”
“The second quarter was an outstanding one at Exogen, and there's a lot to be excited about, so I'll get right into the details. This morning, we reported revenue of $19.9 million, up 16% year-over-year, and the highest quarterly revenue in company history.”
“Today, we reported record first quarter revenue of $17.3 million, up 12% year over year. And with continued improvement in profitability metrics as we execute our plan.”
“I'm pleased to report that Q3 was the strongest quarter in Exagen's history, driven by robust volume growth and continued execution across our commercial, scientific and operational teams.”
“We're excited to report another strong quarter at Exagen, highlighted by record revenue and meaningful progress across our commercial, scientific, and operational efforts.”
